ArticleScientific reports2025
Combining multi-parametric MRI radiomics features with tumor abnormal protein to construct a machine learning-based predictive model for prostate cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Integrated Assessment of Percentage α2,3-Linked Sialylated Prostate-specific Antigen and the Prostate Health Index with Magnetic Resonance Imaging for Detection of Clinically Significant Prostate Cancer.European urology open science · 2026Article
- Artificial intelligence in prostate cancer: navigating the new frontier of precision uro-oncology.American journal of clinical and experimental urology · 2025Review
- Association between abnormal glycoprotein and diabetic peripheral neuropathy in patients with type 2 diabetes mellitus.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
This study aims to investigate the diagnostic value of integrating multi-parametric magnetic resonance imaging (mpMRI) radiomic features with tumor abnormal protein (TAP) and clinical characteristics for diagnosing prostate cancer. A cohort of 109 patients who underwent both mpMRI and TAP assessments prior to prostate biopsy were enrolled. Radiomic features were meticulously extracted from T2-weighted imaging (T2WI) and the apparent diffusion coefficient (ADC) maps. Feature selection was performed using t-tests and the Least Absolute Shrinkage and Selection Operator (LASSO) regression, followed by model construction using the random forest algorithm. To further enhance the model's accuracy and predictive performance, this study incorporated clinical factors including age, serum prostate-specific antigen (PSA) levels, and prostate volume. By integrating these clinical indicators with radiomic features, a more comprehensive and precise predictive model was developed. Finally, the model's performance was quantified by calculating accuracy, sensitivity, specificity, precision, recall, F1 score, and the area under the curve (AUC). From mpMRI sequences of T2WI, dADC(b = 100/1000 s/mm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.